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Melanoma growth and metastasis depend on a battle between the cancer's invasive properties and the host's capacity to counter such attributes. Immunosuppression is a potent promoter of cancer progression that not only counters host control of tumor spread but also prevents anti-cancer treatments from achieving their full benefit ([@R10]). Because CD11b^+^Gr1^+^ cells are most potent at suppressing T-cell function ([@R6]), their exponential proliferation in cancer patients severely limits efficacy of immunotherapy ([@R4]).

We discovered the DC-HIL receptor to potently inhibit effector T-cell function following binding to syndecan-4 (SD-4) on these cells ([@R1]; [@R2]). In a submitted accompanying article, we showed that melanoma-bearing (but not tumor-free) mice harbors an expanded population of DC-HIL-expressing CD11b^+^Gr1^+^ cells and that functional blockade of DC-HIL on these cells via gene deletion or specific Ab abrogates their suppressor function, making DC-HIL a marker for immunosuppressive CD11b^+^Gr1^+^ cells and a powerful promoter of melanoma growth.

Since CD14^+^HLA-DR^no/low^ cells are the human equivalent of mouse CD11b^+^Gr-1^+^ cells ([@R5]), we posited that blood CD14^+^HLA-DR^no/low^ cells in melanoma patients express DC-HIL and that such expression makes them immunosuppressive. Thus we examined blood frequencies of CD14^+^HLA-DR^no/low^ cells and their DC-HIL expression, in cases of: melanoma with varying clinical stages (0-IV) (n=62), dysplastic nevi (in which melanocytes are abnormal but not malignant (n=12)), and healthy donors (n=21) ([Figure 1a](#F1){ref-type="fig"} and [Supplementary Table S1](#SD1){ref-type="supplementary-material"}). Compared to healthy donors, all cases of melanoma exhibited elevated blood CD14^+^HLA-DR^no/low^ cells ([Figure 1b](#F1){ref-type="fig"}), consistent with a prior report ([@R5]). Whereas blood CD14^+^HLA-DR^no/low^ cells in healthy donors had little-to-no expression of DC-HIL (0.1 ± 0.1% DC-HIL^+^ cells among PBMCs), all cases of metastatic melanoma (stages III/IV) displayed high-level DC-HIL expression on these cells (2.9 ± 0.9% and 2.6 ± 0.6%, respectively; *t* test *p*=0.001 vs. healthy donors) ([Figure 1c](#F1){ref-type="fig"}). Intermediate levels of DC-HIL expression were seen in blood CD14^+^HLA-DR^no/low^ cells of melanoma confined to skin (stages 0/I-II). Dysplastic nevi showed lower expression than skin-restricted melanoma, but higher than for healthy donors (*p*=0.01). Thus blood levels of DC-HIL^+^CD14^+^HLA-DR^no/low^ cells correlated with cancer progression, particularly in advanced stages. Other myeloid cells thought to have suppressor function (CD14^+^IL-4Rα^+^, CD14^neg^CD11b^+^CD15^+^, and CD14^neg^IL-4Rα^+^CD15^+^) also expressed DC-HIL at a range of 30--75% ([Supplementary Figure 1](#SD1){ref-type="supplementary-material"}).

To determine whether melanoma was the cause of the elevated blood levels, we followed a new cohort of 9 patients with stage 0 melanoma and assayed for % DC-HIL^+^CD14^+^HLA-DR^no/low^ cells in their PBMCs ([Figure 1d](#F1){ref-type="fig"}), at 0, 1, 3, and 6 months after excision of the melanoma. At the time of resection (0 month), all subjects except one (subject M83) exhibited higher levels than healthy controls (0.3 to 12.8%) ([Supplementary Table S2](#SD1){ref-type="supplementary-material"}). Across the 3-month follow-up, these elevated levels declined significantly in 8 patients (Wald test, *p*=0.045) to an average of 0.4 %, close to that of 6 normal controls ([Supplementary Table S3](#SD1){ref-type="supplementary-material"}). Interestingly, in the case of one patient (M71), the % DC-HIL^+^CD14^+^HLA-DR^no/low^ cells that declined a month post-resection climbed back to a high level at 3 months, which coincided with discovery of a new melanoma *in situ* (stage 0), and then fell back after resection of this second melanoma. We concluded that melanoma is responsible (directly or indirectly) for acquisition of DC-HIL expression by CD14^+^HLA-DR^no/low^ cells. Because our mouse studies showed IFN-γ and IL-1β to induce DC-HIL expression by CD11b^+^Gr1^+^ cells, we speculate similar mechanisms for human CD14^+^HLA-DR^no/low^ cells.

Do CD14^+^HLA-DR^no/low^ cells from melanoma patients suppress T-cell function and is DC-HIL responsible for that function? CD14^+^HLA-DR^no/low^ cells isolated from melanoma patients (vs. healthy donors) were cocultured with autologous T-cells activated by anti-CD2/CD3/CD28 Ab ([Figure 2a](#F2){ref-type="fig"}). CD14^+^HLA-DR^no/low^ cells from melanoma patients inhibited IFN-γ production by autologous T-cells dose-dependently and almost completely, whereas corresponding cells from healthy donors were weakly immunosuppressive.

Treatment with anti-DC-HIL mAb (but not control IgG) restored the T-cell IFN-γ response dose-dependently (up to 80%) ([Figure 2b](#F2){ref-type="fig"}). Moreover, treatment of total (unfractionated) PBMCs from melanoma patients with anti-DC-HIL mAb (but not with control IgG) enhanced the IFN-γ response, and this enhancement correlated positively with melanoma staging ([Figure 2c](#F2){ref-type="fig"}), but negatively with IFN-γ levels from IgG-treated PBMCs ([Figure 2d](#F2){ref-type="fig"}).

Our outcomes indicated that neutralizing DC-HIL's T cell-suppressive function could be beneficial to melanoma patients. Among currently available treatments for melanoma, the most closely related to a DC-HIL antagonist are humanized mAb directed against CTLA-4 (ipilimumab) or PD-1 (lambrolizumab). Both treatments have been shown to prolong survival of patients with metastatic melanoma ([@R8]; [@R9]), presumably by blocking the inhibitory functions of CTLA-4 and PD-1, respectively. However, their benefits have been limited by development of autoimmune disease causing dermatitis, hepatitis, colitis, and in many cases, death ([@R9]), making the search for even better treatments important.

Our mouse studies showed that, unlike DC-HIL, the ligands for CTLA-4 (CD80 and CD86) and for PD-1 (PD-L1) are not critically involved in the T-cell suppressor function of myeloid cells. Moreover, both CTLA-4 and PD-1 are expressed by most activated T-cells and regulate development of autoreactive T-cells via regulatory T-cell function ([@R7]). By contrast, SD-4 (the DC-HIL ligand) is expressed by only a restricted population of effector T-cells, with no impact on regulatory T-cell function ([@R3]). Finally, CTLA-4^−/−^ or PD-1^−/−^ mice develop spontaneous autoimmune diseases ([@R11]; [@R12]) causing early death, while DC-HIL^−/−^ or syndecan-4^−/−^ mice survive without observable autoimmune diseases (unpublished data). These differences suggest strategies neutralizing DC-HIL function may restore T-cell function in melanoma patients via mechanisms different from CTLA-4 or PD-1 blockers.

In sum, the positive correlation between % blood DC-HIL^+^CD14^+^HLA-DR^no/low^ cells and advancing melanoma stage, this parameter's quick decline after resection of early melanoma, and the restoration by anti-DC-HIL mAb of the T-cell IFN-γ response in melanoma patients constitute strong bases for developing these cells as a useful biomarker and therapeutic target for melanoma. Our results should be confirmed by large, multi-centers studies.
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![Positive correlation between DC-HIL^+^CD14^+^HLA-DR^no/low^ cells and melanoma stage\
PBMCs from melanoma patients (stages 0-IV) or dysplastic nevus (DN), and from healthy donors (HD) were analyzed for CD14 vs. HLA-DR expression, in which CD14^+^HLA-DR^no/low^ cells are indicated (%). These cells were FACS-gated and examined for expression of DC-HIL vs. CD14. Data shown are representative of each group **(a**). % CD14^+^HLA-DR^no/low^ (**b**) or % DC-HIL^+^CD14^+^HLA-DR^no/low^ cells/PBMC (**c**) in each cohort is summarized (mean % ± sd). Statistical significance for each stage was calculated by comparison with HD. (**d**) % blood DC-HIL^+^CD14^+^HLA-DR^no/low^ cells/PBMCs was assayed at indicated times post-resection in 9 patients with stage 0 melanoma (data for patient M71 are in red), \**p*\<0.001 and \*\**p*\<0.01.](nihms604600f1){#F1}

![Anti-DC-HIL mAb treatment restored IFN-γ response in melanoma patients\
(**a**) CD14^+^HLA-DR^no/low^ cells from stage III patient or healthy donor cocultured with T-cells/HLA-DR^+^ cells (varying ratios) with anti-CD2/CD3/CD28 Ab. (**b**) Effect of anti-DC-HIL or control IgG on IFN-γ secretion by the coculture (1:1 cell ratio) is expressed as IFN-γ amount (%) relative to T-cell culture: 50 and 53 ng/ml for HD and melanoma, respectively (**a**); and 24 ng/ml for (**b**). Representative data of 3 different patients. (**c**) PBMCs from same patients with stages III/IV were cultured with Ab; fold increase in IFN-γ amounts (mAb vs. IgG) is shown with Pearson's correlation coefficient r. (**d**) Same experiments were performed with all samples, and values of fold increase in IFN-γ production plotted to cancer stage. \**p*\<0.001.](nihms604600f2){#F2}
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